Department of Pharmacology, School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China.
Key Laboratory of Chinese Internal Medicine of MOE, Beijing Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Can J Gastroenterol Hepatol. 2018 Sep 26;2018:6934809. doi: 10.1155/2018/6934809. eCollection 2018.
Liver cancer is one of the leading causes of cancerous deaths worldwide. At present, the treatment of hepatocellular carcinoma (HCC) remains to be a problem globally. Liushenwan (LSW), an ancient Chinese medicine previously used to treat localized infections, was recently reported to possess anticancer activity. Here in this study, we aim to examine the effect of LSW-ET (LSW-ET is the supernatant fraction of LSW from ultrasound assisted ethanol extraction) in prevention and treatment on nanodiethylnitrosamine- (nanoDEN-) induced HCC in mice. In nanoDEN-induced HCC mice treated with LSW-ET by oral (po) or intragastric gavage (ig), we observed an alleviation of serum ALT and AST levels, amelioration in histopathological stainings, and an inhibition in liver tumor growth. In addition, compared with the nanoDEN group, downregulation of multiple pivotal factors (COX-2, -catenin, PCNA, and HMGB-1) was observed in LSW-ET-po and LSW-ET-ig groups. Taken together, the delivery of LSW-ET by oral could be a potential prevention and treatment of liver cancer.
肝癌是全球癌症死亡的主要原因之一。目前,肝细胞癌 (HCC) 的治疗仍然是一个全球性的问题。柳神丸 (LSW) 是一种古老的中药,以前用于治疗局部感染,最近有报道称其具有抗癌活性。在这项研究中,我们旨在研究 LSW-ET(LSW 经超声辅助乙醇提取后的上清液部分)在预防和治疗纳米二乙基亚硝胺 (nanoDEN-) 诱导的小鼠 HCC 中的作用。在通过口服 (po) 或胃内灌胃 (ig) 给予 LSW-ET 的 nanoDEN 诱导的 HCC 小鼠中,我们观察到血清 ALT 和 AST 水平的降低、组织病理学染色的改善以及肝肿瘤生长的抑制。此外,与 nanoDEN 组相比,LSW-ET-po 和 LSW-ET-ig 组中多个关键因子 (COX-2、-catenin、PCNA 和 HMGB-1) 的下调。综上所述,LSW-ET 的口服给药可能是预防和治疗肝癌的一种潜在方法。